Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases

This publication has 24 references indexed in Scilit:

• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• New strategies for cervical cancer screening in adolescents
  Current Opinion in Pediatrics, 2004
• Human papillomavirus and cervical cytology in adolescents
  Adolescnet Medicine Clinics, 2004
• Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  JNCI Journal of the National Cancer Institute, 2004
• Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
  JAMA, 2003
• The causal relation between human papillomavirus and cervical cancer
  Journal of Clinical Pathology, 2002
• The (in)efficiency of cervical screening in Europe
  European Journal Of Cancer, 2002
• Quality assurance in cervical cancer screening: The Icelandic experience 1964–1993
  European Journal Of Cancer, 1995
• Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in iceland, 1964–1991
  International Journal of Cancer, 1993
• The 1988 Bethesda System for Reporting Cervical/Vaginal Cytological Diagnoses
  JAMA, 1989